Michael Dell Just Paid 88% Over Market for This Company

Hey there, bargain hunter. When a billionaire’s family office writes a check 88% above where a stock was trading three months ago, that is not a rounding error. That is a statement. On September 14, 2026, Michael Dell’s DFO Management and AI-focused holding company Sequence Holdings announced a definitive agreement to take The Baldwin Group (BWIN) private in an all-cash deal valued at approximately $7.7 billion, or $32.50 per share.

Scoreboard

Baldwin shareholders will receive $32.50 in cash for each share, representing a premium of approximately 88% to the unaffected closing price on June 17, 2026, the day before media reports that the company was exploring a take-private transaction. The transaction implies a total enterprise value of approximately $7.7 billion, comprised of an equity purchase price of approximately $4.6 billion and approximately $3.1 billion of net debt assumed or refinanced. The deal is expected to close during the first quarter of 2027.

What Actually Happened

Baldwin provides risk management solutions, insurance advisory, and tech-enabled underwriting to businesses and individuals. The public market had been pricing it like a middling broker. DFO and Sequence priced it like a platform.

Sequence is a technology-focused holding company that buys established enterprises in the services industry and then uses AI to further modernize them. DFO is investing directly in the Baldwin deal and also becoming an investor in Sequence. This is not a classic leveraged buyout. It is a technology-led transformation bet, with patient capital behind it. DFO invests with the flexibility and patience of permanent capital, not as a fund working against a fixed exit clock, enabling it to back proven operators for the long term.

The Business

In the first half of 2026, Baldwin grew revenue 29% year-over-year to $1.0 billion, with adjusted EBITDA growing 27% to $254.0 million and an adjusted EBITDA margin of 24.8%. In the second quarter alone, total revenue was $492.9 million, up 30% year-over-year, with adjusted diluted EPS of $0.48, up 14%. Those are not the numbers of a broken company. The market was discounting integration noise and margin pressure, not the franchise.

What the Market Is Really Saying

The broader insurance brokerage sector has been out of favor. Some industry and fund commentary has pointed to insurance brokers lagging the broader equity market over the prior 12 months amid investor concerns about AI’s impact, even as parts of the broader insurance space held up better. That kind of sentiment is the gap Dell just drove a $7.7 billion truck through.

Now run the same screen on what remains. Brown & Brown (BRO) grew Q1 2026 revenue 35.4% to $1.90 billion and trades in the mid-teens on forward earnings estimates, versus the higher multiples the stock has often carried historically. Ryan Specialty (RYAN) posted 11.8% organic growth in Q1 2026, among the best in the peer group, while industry-level price-to-book metrics still screen well below the broader market in many common datasets.

Bull / Base / Bear

• Bull: The Baldwin deal re-rates the entire sector. M&A activity accelerates. BRO and RYAN are next on someone’s screen.
• Base: Sector stays range-bound, but organic growth normalizes higher and margins expand as integrations settle. Patient holders collect a steady re-rating over 12 to 18 months.
• Bear: Macro softens, commercial insurance pricing cools, and organic growth stalls. The M&A premium fades without a follow-on deal.

Action Plan

BWIN is nearly done. The arb spread between the current price and $32.50 is slim, and the deal risk is low given the all-cash structure. Do not chase it.

The real opportunity is in what the deal reveals. BRO is not trading at the premium multiple it has often commanded in stronger sentiment regimes. RYAN, with organic growth around 12% in Q1 2026, is priced as if that growth is temporary. If you are building a position, scale into BRO first on any further sector weakness, and treat RYAN as the higher-conviction, higher-volatility complement.

Cheap Investor Checklist

• BWIN deal: $32.50 all-cash, 88% premium, closing Q1 2027. Arb is thin. Watch for regulatory clearance.
• BRO: Q1 2026 revenue $1.9B (+35.4%). Track whether its forward multiple stays compressed versus its own history.
• RYAN organic growth: 11.8% in Q1 2026, near the top of large-cap peers.
• Sector valuation: Insurance broker industry price-to-book metrics are often quoted around the mid-3x range in industry screens, below broader-market aggregates in many datasets. Sanity-check the inputs before you anchor on it.
• Baldwin H1 2026 adjusted EBITDA margin: 24.8%. Healthy, not distressed.
• Baldwin revenue run-rate: $1.0 billion in six months. $2B+ annualized pace.
• Watch organic growth acceleration: management commentary has pointed to tailwinds in the back half of 2026 as earlier one-time headwinds fade.
• M&A cycle: Sequence and DFO signal that private capital sees more value than public markets do. More deals likely.

Bottom Line

If Dell’s family office paid 88% over market, the question for you is not whether Baldwin was cheap. It was. The question is which broker still sitting in public markets carries the same overlooked franchise value. BRO and RYAN are where that screen points. Buy the sector’s best operators while private capital is still doing your homework for you.